

[ Tue, Jan 09th 2018
] - WOPRAI
[ Tue, Jan 09th 2018
] - WOPRAI
[ Tue, Jan 09th 2018
] - WOPRAI
[ Tue, Jan 09th 2018
] - WOPRAI


[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
Madhu Kumar Initiated (ARWR) at Hold and Held Target at $3 on, Jan 5th, 2018
Madhu Kumar of B. Riley Securities, Initiated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold and Held Target at $3 on, Jan 5th, 2018.
Madhu has made no other calls on ARWR in the last 4 months.
There are 2 other peers that have a rating on ARWR. Out of the 2 peers that are also analyzing ARWR, 0 agree with Madhu's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Madhu
- Edward Tenthoff of "Piper Sandler" Upgraded from Hold to Buy on, Monday, November 27th, 2017
- Y Katherine Xu of "William Blair" Upgraded from Hold to Buy on, Monday, September 18th, 2017